Irritable bowel syndrome is rarely serious, but is still an inconvenience and a painful disorder for patients who have it. For patients who have IBS or are concerned they may have it, how can you explain the basics of how it is detected and managed?
For pediatric patients with nonbloody diarrhea, evaluating symptoms plus blood and stool markers is the optimal test strategy for predicting IBD.
Patients with inflammatory bowel disease had a similar risk for and outcomes from coronavirus disease 2019 as those in the general population.
“These positive preliminary findings represent a major step forward towards bringing an innovative, non-antibiotic option to patients that may help restore their gut microbiome,” said Per Falk, Ferring’s President and Chief Science Officer.
The fact that diarrhea is a symptom in the disease course of some patients with COVID-19 highlights the importance of adhering to preventative measures.
AGA recommends fecal calprotectin, lactoferrin for screening for inflammatory bowel disease.
Researchers evaluated the response of rifaximin therapy in patients with IBS-D with abdominal pain symptoms.
After molecular testing, half of all travel-acquired ESBL-producing E coli strains qualified as pathogens, despite most being classified as extraintestinal pathogenic or uropathogenic.
A recently published report describes the case of a 59-year-old male patient who experienced olmesartan-associated enteropathy (OAE) and highlights the importance of performing thorough medication reviews.
A great deal of progress has been made in reducing the burden of diarrheal diseases, but this reduction has not been equal globally.
